Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial

Published:2012 Issue:2 Volume:82 Page:67-74
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Kaseb A.O.,Garrett-Mayer E.,Morris J.S.,Xiao L.,Lin E.,Onicescu G.,Hassan M.M.,Hassabo H.M.,Iwasaki M.,Deaton F.L.,Abbruzzese J.L.,Thomas M.B.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference26 articles.

1. Sorafenib in Advanced Hepatocellular Carcinoma

2. Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

3. A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

4. Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantification and analyses of seven tyrosine kinase inhibitors targeting hepatocellular carcinoma in human plasma by QuEChERS and UPLC-MS/MS;Journal of Chromatography B;2024-07

2. Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review;TRANSL CANCER RES;2024

3. Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies;Hepatology;2023-05-16

4. A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy;Cancers;2023-04-27

5. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review;International Journal of Molecular Sciences;2022-11-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3